Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Avastin
Pharma
Outlook stock plummets as FDA again snubs wet AMD drug
For the second time, the FDA has declined to approve Outlook's anti-VEGF drug for the treatment of wet age-related macular degeneration.
Angus Liu
Aug 28, 2025 10:55am
Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study
Sep 8, 2024 11:30am
AZ charts new but uncertain path for Imfinzi in liver cancer
Jan 19, 2024 10:00am
FDA signs off on Takeda's colorectal cancer drug Fruzaqla
Nov 9, 2023 10:54am
Merck's Keytruda mostly won out at ESMO, with one notable miss
Oct 24, 2023 9:05am
Roche blasts 'act of counterfeiting' for cancer drug in Pakistan
Sep 25, 2023 2:27pm
